JS-III-49, a hydroquinone derivative, exerts anti-inflammatory activity by targeting Akt and p38

Since previous studies have reported that hydroquinone (HQ) exerted immunosuppressive and anti-inflammatory activity, various HQ derivatives have been synthesized and their biological activities investigated. In this study, we explored the anti-inflammatory activity of JS-III-49, a novel HQ derivati...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of physiology & pharmacology Vol. 21; no. 3; pp. 345 - 352
Main Authors Yi, Young-Su, Kim, Mi-Yeon, Cho, Jae Youl
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Physiological Society and The Korean Society of Pharmacology 01.05.2017
대한약리학회
Subjects
Original
약리학
Anti-inflammatory activity
Akt
p38
HQ derivative
Macrophages
JS-III-49
Online AccessGet full text
ISSN1226-4512
2093-3827
DOI10.4196/kjpp.2017.21.3.345

Cover

Abstract Since previous studies have reported that hydroquinone (HQ) exerted immunosuppressive and anti-inflammatory activity, various HQ derivatives have been synthesized and their biological activities investigated. In this study, we explored the anti-inflammatory activity of JS-III-49, a novel HQ derivative, in macrophage-mediated inflammatory responses. JS-III-49 suppressed the production of the inflammatory mediators nitric oxide (NO) and prostaglandin E (PGE ) and down-regulated the mRNA expression of the inflammatory enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) as well as the expression of the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-1b without cytotoxicity in LPS-stimulated RAW264.7 cells. JS-III-49 inhibited nuclear translocation of the NF-kB transcription factors p65 and p50 by directly targeting Akt, an upstream kinase of the NF-kB pathway, in LPS-stimulated RAW264.7 cells. However, JS-III-49 did not directly inhibit the kinase activities of Src and Syk, which are upstream kinases of Akt, in LPS-stimulated RAW264.7 cells. Moreover, JS-III-49 suppressed the nuclear translocation of c-Fos, one of the components of AP-1, by specifically targeting p38, an upstream mitogen-activated protein kinase (MAPK) in the AP-1 pathway in LPS-stimulated RAW264.7 cells. These results suggest that JS-III-49 plays an anti-inflammatory role in LPS-stimulated macrophages by targeting Akt and p38 in the NF-kB and AP-1 pathways, respectively.
AbstractList Since previous studies have reported that hydroquinone (HQ) exerted immunosuppressive and anti-inflammatory activity, various HQ derivatives have been synthesized and their biological activities investigated. In this study, we explored the anti-inflammatory activity of JS-III-49, a novel HQ derivative, in macrophage-mediated inflammatory responses. JS-III-49 suppressed the production of the inflammatory mediators nitric oxide (NO) and prostaglandin E (PGE ) and down-regulated the mRNA expression of the inflammatory enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) as well as the expression of the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-1b without cytotoxicity in LPS-stimulated RAW264.7 cells. JS-III-49 inhibited nuclear translocation of the NF-kB transcription factors p65 and p50 by directly targeting Akt, an upstream kinase of the NF-kB pathway, in LPS-stimulated RAW264.7 cells. However, JS-III-49 did not directly inhibit the kinase activities of Src and Syk, which are upstream kinases of Akt, in LPS-stimulated RAW264.7 cells. Moreover, JS-III-49 suppressed the nuclear translocation of c-Fos, one of the components of AP-1, by specifically targeting p38, an upstream mitogen-activated protein kinase (MAPK) in the AP-1 pathway in LPS-stimulated RAW264.7 cells. These results suggest that JS-III-49 plays an anti-inflammatory role in LPS-stimulated macrophages by targeting Akt and p38 in the NF-kB and AP-1 pathways, respectively.
Since previous studies have reported that hydroquinone (HQ) exerted immunosuppressive and anti-inflammatory activity, various HQ derivatives have been synthesized and their biological activities investigated. In this study, we explored the anti-inflammatory activity of JS-III-49, a novel HQ derivative, in macrophage-mediated inflammatory responses. JS-III-49 suppressed the production of the inflammatory mediators nitric oxide (NO) and prostaglandin E 2 (PGE 2 ) and down-regulated the mRNA expression of the inflammatory enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) as well as the expression of the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-1b without cytotoxicity in LPS-stimulated RAW264.7 cells. JS-III-49 inhibited nuclear translocation of the NF-kB transcription factors p65 and p50 by directly targeting Akt, an upstream kinase of the NF-kB pathway, in LPS-stimulated RAW264.7 cells. However, JS-III-49 did not directly inhibit the kinase activities of Src and Syk, which are upstream kinases of Akt, in LPS-stimulated RAW264.7 cells. Moreover, JS-III-49 suppressed the nuclear translocation of c-Fos, one of the components of AP-1, by specifically targeting p38, an upstream mitogen-activated protein kinase (MAPK) in the AP-1 pathway in LPS-stimulated RAW264.7 cells. These results suggest that JS-III-49 plays an anti-inflammatory role in LPS-stimulated macrophages by targeting Akt and p38 in the NF-kB and AP-1 pathways, respectively.
Since previous studies have reported that hydroquinone (HQ) exerted immunosuppressive and anti-inflammatory activity, various HQ derivatives have been synthesized and their biological activities investigated. In this study, we explored the anti-inflammatory activity of JS-III-49, a novel HQ derivative, in macrophagemediated inflammatory responses. JS-III-49 suppressed the production of the inflammatory mediators nitric oxide (NO) and prostaglandin E2 (PGE2) and downregulated the mRNA expression of the inflammatory enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) as well as the expression of the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-1b without cytotoxicity in LPS-stimulated RAW264.7 cells. JS-III-49 inhibited nuclear translocation of the NF-kB transcription factors p65 and p50 by directly targeting Akt, an upstream kinase of the NF-kB pathway, in LPS-stimulated RAW264.7 cells. However, JS-III-49 did not directly inhibit the kinase activities of Src and Syk, which are upstream kinases of Akt, in LPSstimulated RAW264.7 cells. Moreover, JS-III-49 suppressed the nuclear translocation of c-Fos, one of the components of AP-1, by specifically targeting p38, an upstream mitogen-activated protein kinase (MAPK) in the AP-1 pathway in LPS-stimulated RAW264.7 cells. These results suggest that JS-III-49 plays an anti-inflammatory role in LPS-stimulated macrophages by targeting Akt and p38 in the NF-kB and AP-1 pathways, respectively. KCI Citation Count: 2
Since previous studies have reported that hydroquinone (HQ) exerted immunosuppressive and anti-inflammatory activity, various HQ derivatives have been synthesized and their biological activities investigated. In this study, we explored the anti-inflammatory activity of JS-III-49, a novel HQ derivative, in macrophage-mediated inflammatory responses. JS-III-49 suppressed the production of the inflammatory mediators nitric oxide (NO) and prostaglandin E2 (PGE2) and down-regulated the mRNA expression of the inflammatory enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) as well as the expression of the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-1b without cytotoxicity in LPS-stimulated RAW264.7 cells. JS-III-49 inhibited nuclear translocation of the NF-kB transcription factors p65 and p50 by directly targeting Akt, an upstream kinase of the NF-kB pathway, in LPS-stimulated RAW264.7 cells. However, JS-III-49 did not directly inhibit the kinase activities of Src and Syk, which are upstream kinases of Akt, in LPS-stimulated RAW264.7 cells. Moreover, JS-III-49 suppressed the nuclear translocation of c-Fos, one of the components of AP-1, by specifically targeting p38, an upstream mitogen-activated protein kinase (MAPK) in the AP-1 pathway in LPS-stimulated RAW264.7 cells. These results suggest that JS-III-49 plays an anti-inflammatory role in LPS-stimulated macrophages by targeting Akt and p38 in the NF-kB and AP-1 pathways, respectively.Since previous studies have reported that hydroquinone (HQ) exerted immunosuppressive and anti-inflammatory activity, various HQ derivatives have been synthesized and their biological activities investigated. In this study, we explored the anti-inflammatory activity of JS-III-49, a novel HQ derivative, in macrophage-mediated inflammatory responses. JS-III-49 suppressed the production of the inflammatory mediators nitric oxide (NO) and prostaglandin E2 (PGE2) and down-regulated the mRNA expression of the inflammatory enzymes cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) as well as the expression of the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-1b without cytotoxicity in LPS-stimulated RAW264.7 cells. JS-III-49 inhibited nuclear translocation of the NF-kB transcription factors p65 and p50 by directly targeting Akt, an upstream kinase of the NF-kB pathway, in LPS-stimulated RAW264.7 cells. However, JS-III-49 did not directly inhibit the kinase activities of Src and Syk, which are upstream kinases of Akt, in LPS-stimulated RAW264.7 cells. Moreover, JS-III-49 suppressed the nuclear translocation of c-Fos, one of the components of AP-1, by specifically targeting p38, an upstream mitogen-activated protein kinase (MAPK) in the AP-1 pathway in LPS-stimulated RAW264.7 cells. These results suggest that JS-III-49 plays an anti-inflammatory role in LPS-stimulated macrophages by targeting Akt and p38 in the NF-kB and AP-1 pathways, respectively.
Author Yi, Young-Su
Kim, Mi-Yeon
Cho, Jae Youl
AuthorAffiliation 1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 16419, Korea
3 School of Systems Biomedical Science, Soongsil University, Seoul 06978, Korea
2 Department of Pharmaceutical Engineering, Cheongju University, Cheongju 28503, Korea
AuthorAffiliation_xml – name: 2 Department of Pharmaceutical Engineering, Cheongju University, Cheongju 28503, Korea
– name: 3 School of Systems Biomedical Science, Soongsil University, Seoul 06978, Korea
– name: 1 Department of Genetic Engineering, Sungkyunkwan University, Suwon 16419, Korea
Author_xml – sequence: 1
  givenname: Young-Su
  surname: Yi
  fullname: Yi, Young-Su
  organization: Department of Genetic Engineering, Sungkyunkwan University, Suwon 16419, Korea., Department of Pharmaceutical Engineering, Cheongju University, Cheongju 28503, Korea
– sequence: 2
  givenname: Mi-Yeon
  surname: Kim
  fullname: Kim, Mi-Yeon
  organization: School of Systems Biomedical Science, Soongsil University, Seoul 06978, Korea
– sequence: 3
  givenname: Jae Youl
  surname: Cho
  fullname: Cho, Jae Youl
  organization: Department of Genetic Engineering, Sungkyunkwan University, Suwon 16419, Korea
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28461777$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002217152$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kUtv1DAUhS1URKelf4AF8hKkJvgde4M0qloIqoQE7dp1HGdqJi8cz6j59zidUgELVnfh75xzr88JOOqH3gHwBqOcYSU-bH-MY04QLnKCc5pTxl-AFUGKZlSS4gisMCEiYxyTY3A2Tb5CSHLEJVKvwDGRTOCiKFbg7sv3rCzLjKlzaOD9XIfh584vWbB2we9N9Ht3Dt2DC3GCpo8-833Tmq4zcQgzNDYBPs6wmmE0YeOi7zdwvY2JreFI5WvwsjHt5M6e5im4vbq8uficXX_9VF6srzPLqIiZLChVtRCmEkwwpKQVNafSGqGUY6IghlTcOYXqiopGKYOUK6q6skW6tsaGnoL3B98-NHprvR6Mf5ybQW-DXn-7KTWmgmDCE_vxwI67qnO1dX0MptVj8J0J86Py75fe3yefveZpM4xVMnj3ZLB8l5ui7vxkXdua3g27SWOpGCeIsQV9-2fWc8jvChJADoANwzQF1zwjGOmlar1UrZeqNcGa6lR1Esl_RNbH1NWw7Ovb_0l_AUMXryA
CitedBy_id crossref_primary_10_1016_j_intimp_2020_107017
crossref_primary_10_1155_2017_3619879
crossref_primary_10_1016_j_jgr_2018_10_003
crossref_primary_10_3389_fphar_2022_882924
Cites_doi 10.4062/biomolther.2015.036
10.1124/mol.64.2.211
10.1016/S1016-8478(23)07374-0
10.1124/mol.58.5.1026
10.4062/biomolther.2014.088
10.1016/j.imlet.2004.11.025
10.1038/sj.leu.2401981
10.1016/j.jep.2009.12.042
10.1006/taap.1996.0171
10.1016/j.jgr.2016.07.006
10.1211/0022357055731
10.5483/BMBRep.2015.48.9.259
10.4196/kjpp.2016.20.1.91
10.1080/10408449991349221
10.1016/j.clinthera.2008.03.002
10.1016/j.jgr.2016.08.003
10.1016/j.ejmech.2013.04.070
10.1074/jbc.M109.074872
10.1023/A:1007644620655
10.4196/kjpp.2015.19.5.441
10.1146/annurev.immunol.23.021704.115816
10.1016/j.jep.2014.10.064
10.1016/S0014-2999(00)00337-X
10.1016/0003-2697(82)90118-X
10.1016/j.jgr.2014.10.004
10.1016/j.jgr.2014.06.002
10.1046/j.1365-2567.2002.01451.x
10.1007/s12272-001-1161-1
10.4062/biomolther.2016.027
10.1111/j.1365-2249.2006.03261.x
10.1016/j.jep.2011.07.048
10.1016/0022-1759(86)90215-2
10.1016/j.jep.2013.12.009
ContentType Journal Article
Copyright Copyright © Korean J Physiol Pharmacol 2017
Copyright_xml – notice: Copyright © Korean J Physiol Pharmacol 2017
DBID AAYXX
CITATION
NPM
7X8
5PM
ACYCR
DOI 10.4196/kjpp.2017.21.3.345
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 2093-3827
EndPage 352
ExternalDocumentID oai_kci_go_kr_ARTI_1362125
PMC5409119
28461777
10_4196_kjpp_2017_21_3_345
Genre Journal Article
GrantInformation_xml – fundername: ;
GroupedDBID ---
5-W
53G
5GY
8JR
8XY
9ZL
AAYXX
ABDBF
ACUHS
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
ESX
F5P
GX1
HYE
KVFHK
MK0
OK1
P2P
P5Y
P6G
RPM
TR2
TUS
NPM
7X8
5PM
.UV
ABPTK
ACYCR
ID FETCH-LOGICAL-c436t-87339d66ab6464098c6d538ca699e4672a2b5ee90db36f99a09e7bdbc7827d1a3
ISSN 1226-4512
IngestDate Tue Nov 21 21:12:39 EST 2023
Thu Aug 21 13:58:10 EDT 2025
Fri Jul 11 09:14:11 EDT 2025
Thu Apr 03 06:59:35 EDT 2025
Tue Jul 01 02:33:16 EDT 2025
Thu Apr 24 23:12:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Anti-inflammatory activity
Akt
p38
HQ derivative
Macrophages
JS-III-49
Language English
License http://creativecommons.org/licenses/by-nc/4.0
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c436t-87339d66ab6464098c6d538ca699e4672a2b5ee90db36f99a09e7bdbc7827d1a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
G704-000764.2017.21.3.008
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC5409119
PMID 28461777
PQID 1894520449
PQPubID 23479
PageCount 8
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_1362125
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5409119
proquest_miscellaneous_1894520449
pubmed_primary_28461777
crossref_primary_10_4196_kjpp_2017_21_3_345
crossref_citationtrail_10_4196_kjpp_2017_21_3_345
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-05-01
PublicationDateYYYYMMDD 2017-05-01
PublicationDate_xml – month: 05
  year: 2017
  text: 2017-05-01
  day: 01
PublicationDecade 2010
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle The Korean journal of physiology & pharmacology
PublicationTitleAlternate Korean J Physiol Pharmacol
PublicationYear 2017
Publisher The Korean Physiological Society and The Korean Society of Pharmacology
대한약리학회
Publisher_xml – name: The Korean Physiological Society and The Korean Society of Pharmacology
– name: 대한약리학회
References Cho (10.4196/kjpp.2017.21.3.345_ref27) 2000; 398
Green (10.4196/kjpp.2017.21.3.345_ref26) 1982; 126
Yang (10.4196/kjpp.2017.21.3.345_ref9) 2014
Gerlier (10.4196/kjpp.2017.21.3.345_ref28) 1986; 94
Kaur (10.4196/kjpp.2017.21.3.345_ref2) 2013; 67
Yu (10.4196/kjpp.2017.21.3.345_ref8) 2012
Taylor (10.4196/kjpp.2017.21.3.345_ref4) 2005; 23
McDonald (10.4196/kjpp.2017.21.3.345_ref17) 2001; 15
Lee (10.4196/kjpp.2017.21.3.345_ref25) 2002; 106
Kim (10.4196/kjpp.2017.21.3.345_ref18) 2005; 57
Lee (10.4196/kjpp.2017.21.3.345_ref22) 2007; 23
Ha (10.4196/kjpp.2017.21.3.345_ref41) 2016; 12
DeCaprio (10.4196/kjpp.2017.21.3.345_ref16) 1999; 29
Kim (10.4196/kjpp.2017.21.3.345_ref14) 2016; 20
Ma (10.4196/kjpp.2017.21.3.345_ref21) 2003; 64
Hossen (10.4196/kjpp.2017.21.3.345_ref39) 2015; 159
Shao (10.4196/kjpp.2017.21.3.345_ref5) 2015; 23
Yi (10.4196/kjpp.2017.21.3.345_ref7) 2014
Sung (10.4196/kjpp.2017.21.3.345_ref11) 2015; 19
Yu (10.4196/kjpp.2017.21.3.345_ref32) 2011; 137
Choi (10.4196/kjpp.2017.21.3.345_ref35) 2012
Park (10.4196/kjpp.2017.21.3.345_ref29) 2016; 40
Seo (10.4196/kjpp.2017.21.3.345_ref15) 2015; 48
Jeong (10.4196/kjpp.2017.21.3.345_ref34) 2014; 151
Yu (10.4196/kjpp.2017.21.3.345_ref40) 2014
Ferrero-Miliani (10.4196/kjpp.2017.21.3.345_ref1) 2007; 147
Choi (10.4196/kjpp.2017.21.3.345_ref24) 2008; 31
Baek (10.4196/kjpp.2017.21.3.345_ref31) 2016; 40
Baek (10.4196/kjpp.2017.21.3.345_ref10) 2015; 39
Li (10.4196/kjpp.2017.21.3.345_ref23) 1996; 139
Kim (10.4196/kjpp.2017.21.3.345_ref36) 2005; 99
Yang (10.4196/kjpp.2017.21.3.345_ref38) 2016; 24
Lee (10.4196/kjpp.2017.21.3.345_ref20) 2010; 285
Pyatt (10.4196/kjpp.2017.21.3.345_ref19) 2000; 16
Yu (10.4196/kjpp.2017.21.3.345_ref33) 2010; 128
Boer (10.4196/kjpp.2017.21.3.345_ref37) 2000; 58
Byeon (10.4196/kjpp.2017.21.3.345_ref6) 2012
Massarotti (10.4196/kjpp.2017.21.3.345_ref3) 2008; 30
Yang (10.4196/kjpp.2017.21.3.345_ref13) 2015; 39
Kim (10.4196/kjpp.2017.21.3.345_ref12) 2015; 23
Yang (10.4196/kjpp.2017.21.3.345_ref30) 2013
References_xml – volume: 23
  start-page: 414
  year: 2015
  ident: 10.4196/kjpp.2017.21.3.345_ref12
  publication-title: Biomol Ther (Seoul)
  doi: 10.4062/biomolther.2015.036
– volume: 64
  start-page: 211
  year: 2003
  ident: 10.4196/kjpp.2017.21.3.345_ref21
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.64.2.211
– volume: 23
  start-page: 198
  year: 2007
  ident: 10.4196/kjpp.2017.21.3.345_ref22
  publication-title: Mol Cells
  doi: 10.1016/S1016-8478(23)07374-0
– volume: 12
  start-page: 295
  year: 2016
  ident: 10.4196/kjpp.2017.21.3.345_ref41
  publication-title: Pharmacogn Mag
– volume: 58
  start-page: 1026
  year: 2000
  ident: 10.4196/kjpp.2017.21.3.345_ref37
  publication-title: Mol Pharmacol
  doi: 10.1124/mol.58.5.1026
– volume: 23
  start-page: 39
  year: 2015
  ident: 10.4196/kjpp.2017.21.3.345_ref5
  publication-title: Biomol Ther (Seoul)
  doi: 10.4062/biomolther.2014.088
– year: 2014
  ident: 10.4196/kjpp.2017.21.3.345_ref9
  publication-title: Mediators Inflamm
– volume: 99
  start-page: 24
  year: 2005
  ident: 10.4196/kjpp.2017.21.3.345_ref36
  publication-title: Immunol Lett
  doi: 10.1016/j.imlet.2004.11.025
– year: 2014
  ident: 10.4196/kjpp.2017.21.3.345_ref40
  publication-title: Mediators Inflamm
– volume: 15
  start-page: 10
  year: 2001
  ident: 10.4196/kjpp.2017.21.3.345_ref17
  publication-title: Leukemia
  doi: 10.1038/sj.leu.2401981
– year: 2012
  ident: 10.4196/kjpp.2017.21.3.345_ref35
  publication-title: Evid Based Complement Alternat Med
– volume: 128
  start-page: 139
  year: 2010
  ident: 10.4196/kjpp.2017.21.3.345_ref33
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2009.12.042
– volume: 139
  start-page: 317
  year: 1996
  ident: 10.4196/kjpp.2017.21.3.345_ref23
  publication-title: Toxicol Appl Pharmacol
  doi: 10.1006/taap.1996.0171
– volume: 40
  start-page: 431
  year: 2016
  ident: 10.4196/kjpp.2017.21.3.345_ref29
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2016.07.006
– volume: 57
  start-page: 475
  year: 2005
  ident: 10.4196/kjpp.2017.21.3.345_ref18
  publication-title: J Pharm Pharmacol
  doi: 10.1211/0022357055731
– volume: 48
  start-page: 495
  year: 2015
  ident: 10.4196/kjpp.2017.21.3.345_ref15
  publication-title: BMB Rep
  doi: 10.5483/BMBRep.2015.48.9.259
– volume: 20
  start-page: 91
  year: 2016
  ident: 10.4196/kjpp.2017.21.3.345_ref14
  publication-title: Korean J Physiol Pharmacol
  doi: 10.4196/kjpp.2016.20.1.91
– volume: 29
  start-page: 283
  year: 1999
  ident: 10.4196/kjpp.2017.21.3.345_ref16
  publication-title: Crit Rev Toxicol
  doi: 10.1080/10408449991349221
– volume: 30
  start-page: 429
  year: 2008
  ident: 10.4196/kjpp.2017.21.3.345_ref3
  publication-title: Clin Ther
  doi: 10.1016/j.clinthera.2008.03.002
– volume: 40
  start-page: 437
  year: 2016
  ident: 10.4196/kjpp.2017.21.3.345_ref31
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2016.08.003
– volume: 67
  start-page: 434
  year: 2013
  ident: 10.4196/kjpp.2017.21.3.345_ref2
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2013.04.070
– volume: 285
  start-page: 9932
  year: 2010
  ident: 10.4196/kjpp.2017.21.3.345_ref20
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.074872
– volume: 16
  start-page: 41
  year: 2000
  ident: 10.4196/kjpp.2017.21.3.345_ref19
  publication-title: Cell Biol Toxicol
  doi: 10.1023/A:1007644620655
– volume: 19
  start-page: 441
  year: 2015
  ident: 10.4196/kjpp.2017.21.3.345_ref11
  publication-title: Korean J Physiol Pharmacol
  doi: 10.4196/kjpp.2015.19.5.441
– volume: 23
  start-page: 901
  year: 2005
  ident: 10.4196/kjpp.2017.21.3.345_ref4
  publication-title: Annu Rev Immunol
  doi: 10.1146/annurev.immunol.23.021704.115816
– volume: 159
  start-page: 9
  year: 2015
  ident: 10.4196/kjpp.2017.21.3.345_ref39
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2014.10.064
– volume: 398
  start-page: 399
  year: 2000
  ident: 10.4196/kjpp.2017.21.3.345_ref27
  publication-title: Eur J Pharmacol
  doi: 10.1016/S0014-2999(00)00337-X
– volume: 126
  start-page: 131
  year: 1982
  ident: 10.4196/kjpp.2017.21.3.345_ref26
  publication-title: Anal Biochem
  doi: 10.1016/0003-2697(82)90118-X
– volume: 39
  start-page: 155
  year: 2015
  ident: 10.4196/kjpp.2017.21.3.345_ref10
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2014.10.004
– volume: 39
  start-page: 61
  year: 2015
  ident: 10.4196/kjpp.2017.21.3.345_ref13
  publication-title: J Ginseng Res
  doi: 10.1016/j.jgr.2014.06.002
– year: 2012
  ident: 10.4196/kjpp.2017.21.3.345_ref8
  publication-title: Mediators Inflamm
– volume: 106
  start-page: 496
  year: 2002
  ident: 10.4196/kjpp.2017.21.3.345_ref25
  publication-title: Immunology
  doi: 10.1046/j.1365-2567.2002.01451.x
– year: 2014
  ident: 10.4196/kjpp.2017.21.3.345_ref7
  publication-title: Mediators Inflamm
– volume: 31
  start-page: 337
  year: 2008
  ident: 10.4196/kjpp.2017.21.3.345_ref24
  publication-title: Arch Pharm Res
  doi: 10.1007/s12272-001-1161-1
– year: 2012
  ident: 10.4196/kjpp.2017.21.3.345_ref6
  publication-title: Mediators Inflamm
– volume: 24
  start-page: 595
  year: 2016
  ident: 10.4196/kjpp.2017.21.3.345_ref38
  publication-title: Biomol Ther (Seoul)
  doi: 10.4062/biomolther.2016.027
– volume: 147
  start-page: 227
  year: 2007
  ident: 10.4196/kjpp.2017.21.3.345_ref1
  publication-title: Clin Exp Immunol
  doi: 10.1111/j.1365-2249.2006.03261.x
– volume: 137
  start-page: 1197
  year: 2011
  ident: 10.4196/kjpp.2017.21.3.345_ref32
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2011.07.048
– year: 2013
  ident: 10.4196/kjpp.2017.21.3.345_ref30
  publication-title: Mediators Inflamm
– volume: 94
  start-page: 57
  year: 1986
  ident: 10.4196/kjpp.2017.21.3.345_ref28
  publication-title: J Immunol Methods
  doi: 10.1016/0022-1759(86)90215-2
– volume: 151
  start-page: 960
  year: 2014
  ident: 10.4196/kjpp.2017.21.3.345_ref34
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2013.12.009
SSID ssib008505809
ssj0064464
Score 2.0669472
Snippet Since previous studies have reported that hydroquinone (HQ) exerted immunosuppressive and anti-inflammatory activity, various HQ derivatives have been...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 345
SubjectTerms Original
약리학
Title JS-III-49, a hydroquinone derivative, exerts anti-inflammatory activity by targeting Akt and p38
URI https://www.ncbi.nlm.nih.gov/pubmed/28461777
https://www.proquest.com/docview/1894520449
https://pubmed.ncbi.nlm.nih.gov/PMC5409119
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002217152
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX The Korean Journal of Physiology & Pharmacology, 2017, 21(3), , pp.345-352
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa68cILAsal3GQQ4mVzaeI0iR-nCliHhiZtk7onEycOLV0vKilS-a38GM6xnUu7CcFe0sqNayffp3Oxzzkm5C33E0-BZmS5yGMGGi9kSe4ppnUcgP0aplEP851PvoRHF8HxsDdstX43opZWheqkv27MK7kNqtAGuGKW7H8gW_0pNMB3wBeugDBc_wnj4zM2GAxYIEwM5v5onaGcH4NHj9lQS3Nw2U-zYoknKxVYjrkYMxgZaDC12-uY12COj0Az1ESFm3WSiQ08X9iaKKX1ipz6PF-Wi_fOkDWLI7aUE_JoURfDrpbrL03MgJEs7GxV7_vb9dgxu9R1NEB_ZDeDEo0drprLEgB2FQTYKRPb3IROy1kY1pXBqPgQjZvKZgz8256mlcxgJ7Kg52KutWnzu4IzHtviAqU4twnXjra8IZu5rVvp1Dy3hXO3NUgAEglgn3xfYDFTL-r4Xod3XNcGpRZTwylQ7kB0dxDNZt3u05M-WMOgS8QOueNHkQki-DSspWkMxqcpnmbtBjBMTbGz6kFtihdO6P316WARazf2hkW1M1vmNzlL2zG_DSPq_D6557wfemip_IC09Owh2TucARena_qOViCu98jXit0HNKFNbtOa2wfUMpteYzYtmU3VmlbMpsBsuDejwOxH5OLjh_P-EXPngbA04GEBiptzkYVhokJ4VV0Rp2EG-jpNQiE0KHw_8VVPa9HNFA9zIZKu0JHKVApWcJR5CX9MdnGWTwkFzyLNwVPQPU8HUeILFasceoaep1I_523ile9Upq5YPp7ZciXBaUZIJEIiERLpe5JLgKRN9qs-C1sq5q93vwGo5CQdS6zwjp_f5nKylODHDqQHdiW4Hm3yukRSgtjHvbxkpuerH9KLRdDzu0Eg2uSJRbYatCRGm0QbmFc34ICbv8zGI1Na3jH22a17Pid3a2nwguwWy5V-CWZ7oV4Z9v8B20btAQ
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=JS-III-49%2C+a+hydroquinone+derivative%2C+exerts+anti-inflammatory+activity+by+targeting+Akt+and+p38&rft.jtitle=The+Korean+journal+of+physiology+%26+pharmacology&rft.au=Yi%2C+Young-Su&rft.au=Kim%2C+Mi-Yeon&rft.au=Cho%2C+Jae+Youl&rft.date=2017-05-01&rft.pub=The+Korean+Physiological+Society+and+The+Korean+Society+of+Pharmacology&rft.issn=1226-4512&rft.eissn=2093-3827&rft.volume=21&rft.issue=3&rft.spage=345&rft.epage=352&rft_id=info:doi/10.4196%2Fkjpp.2017.21.3.345&rft_id=info%3Apmid%2F28461777&rft.externalDocID=PMC5409119
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1226-4512&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1226-4512&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1226-4512&client=summon